Navigation Links
Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation
Date:5/20/2011

ments regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts:

Media:
Fritz Bittenbender
610-883-5855 (office)

610-457-7041 (cell)
fbittenb@cephalon.com

Natalie de Vane
610-727-6536 (office)
610-999-8756 (cell)
ndevane@cephalon.com

Investor Relations:
Chip Merritt
610-738-6376 (office)
cmerritt@cephalon.com

Joseph Marczely
610-883-5894 (office)
jmarczely@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
2. Cephalon Recommends Shareholders Reject Valeant Nominees
3. Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
4. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
5. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
6. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
7. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
8. Cephalon Reports Record Earnings and Raises 2010 Guidance
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
11. Cephalon Completes Acquisition of Arana Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in ... product from a new partner. STT-Systems has developed ... 15 years, with offerings in the optical-motion capture, 3D scanning, ... (inertial measurement unit), iSen, is opening eyes around the world. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... ... ... -- DuPont has entered into agreements to acquire AgVenture, Kentland, Ind.; Hoegemeyer Hybrids, ... business’ PROaccess℠ strategy. Closings are scheduled to occur in the latter part of 2010. ...
... 2 Repligen Corporation (Nasdaq: RGEN ) announced today that it ... on Wednesday, June 9th, 2010 , before the market opens.  The Company ... a conference call and webcast on the same day at 10:00 a.m. ... the Company. , , , ...
... FT. MYERS, Fla., June 2 NeoGenomics, ... will present at the Sixth Annual Noble Financial Equity Conference ... 7, 2010 at the Seminole Hard Rock Hotel in ... Chief Scientific Officer, will give a presentation regarding NeoGenomics, market ...
Cached Biology Technology:DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 2DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 3DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Recognition Market 2015-2019" report to their offering. ... recognition is a technology used for the identification of ... of a person such as nose, jaw edges, mouth, ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... COLUMBIA, Mo. -- Resveratrol, a compound found commonly in ... have several beneficial effects on human health, including cardiovascular ... researcher has discovered that the compound can make prostate ... chances of a full recovery from all types of ...
... nonfood substances, such as earth -- and amylophagy, eating raw ... the U.S. Some 180 species of animals are also known ... A study appearing Oct. 17 in the online journal ... of pica in Madagascar. It is one of only a ...
... Society of Environmental Toxicology and Chemistry will present the SETAC/ICA ... Annual Meeting, November 11 at the Long Beach Convention and ... School of Marine & Atmospheric Science of the University of ... understanding of fate and effects of metals in the environment, ...
Cached Biology News:Compound in grapes, red wine could be key to fighting prostate cancer 2Study documents eating of soil, raw starch in Madagascar 2SETAC announces Chris Lee Award for metals research winner, Kevin Brix 2
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
... (Ser843) Immunogen: ... encompassing the human, mouse, and rat ... Number: NM_153831 ... by immunoblot. ...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: